StockNews.com lowered shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a hold rating to a sell rating in a research report released on Wednesday. PTGX has been the topic of several other reports. JMP Securities lifted their target price on Protagonist Therapeutics from $28.00 to $35.00 in a report on Thursday, July 6th. HC […]